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Abstract
Acute Respiratory Distress Syndrome (ARDS) is a common entity 
in critical care. ARDS is associated with many diagnoses, including 
trauma and sepsis, can lead to multiple organ failure and has high 
mortality. The present article is a narrative review of the literature 
on ARDS, including ARDS pathophysiology and therapeutic op-
tions currently being evaluated or in use in clinical practice. The 
literature review covers relevant publications until January 2011. 
Recent developments in the therapeutic approach to ARDS in-
clude refinements of mechanical ventilatory support with emphasis 
on protective lung ventilation using low tidal volumes, increased 
PEEP with use of recruitment maneuvers to promote reopening of 
collapsed lung alveoli, prone position as rescue therapy for severe 
hypoxemia, and high frequency ventilation. Supportive measures 
in the management of ARDS include attention to fluid balance, re-
strictive transfusion strategies, and minimization of sedatives and 
neuromuscular blocking agents. Inhaled bronchodilators such as 
inhaled nitric oxide and prostaglandins confer short term improve-
ment without proven effect on survival, but are currently used in 
many centers. Use of corticosteroids is also important, and appro-
priate timely use may reduce mortality. Finally, extra corporeal 
oxygenation methods are very useful as rescue therapy in patients 
with intractable hypoxemia, even though a survival benefit has not, 
to this date been demonstrated. Despite intense ongoing research 
on the pathophysiology and treatment of ARDS, mortality remains 
high. Many pharmacologic and supportive strategies have shown 
promising results, but data from large randomized clinical trials are 
needed to fully evaluate the true effectiveness of these therapies.
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Introduction
In 1821, Laennec described a new syndrome characterized 
by pulmonary edema without heart failure [1]. Subsequently, 
several terms, such as “double pneumonia”, “shock lung” 
and “post traumatic lung” have been used to describe this 
syndrome. The term “Acute Respiratory Distress Syndrome” 
was first used in 1967 to describe a distinct clinical entity 
characterized by acute abnormality of both lungs [2].
In 1994, the American-European Consensus Conference 
on ARDS established criteria for the diagnosis of ARDS. 
These criteria include acute onset, bilateral lung infiltrates, 
no evidence of elevated left atrial pressure and arterial oxy-
gen tension to inspired oxygen fraction (PaO2/FiO2) less 
than 200. The diagnosis of ARDS requires all these features. 
However, as these clinical criteria do not always correlate 
well with diffuse alveolar damage, which is the typical patho-
logic ARDS feature, ARDS remains a syndrome associated 
with multiple diagnoses [3], rather than a disease in itself.
Despite substantial progress in understanding ARDS 
pathophysiology, ARDS remains a major clinical problem, 
and mortality is still as high as 40 - 46%. The incidence of 
ARDS in the Intensive Care Unit (ICU) ranges between 4% 
to 9% depending on patient age and study population [4].
Pathophysiology
Increased capillary permeability is the hallmark of ARDS. 
Damage of the capillary endothelium and alveolar epitheli-
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um in correlation to impaired fluid remove from the alveolar 
space result in accumulation of protein-rich fluid inside the 
alveoli, thereby producing diffuse alveolar damage, with re-
lease of pro-inflammatory cytokines, such as Tumor Necro-
sis Factor (TNF), IL-1 and IL-6 [5]. Neutrophils are recruited 
to the lungs by cytokines, become activated and release toxic 
mediators, such as reactive oxygen species and proteases [6]. 
Extensive free radical production overwhelms endogenous 
anti-oxidants and causes oxidative cell damage [7].
Inflammation due to neutrophil activation is key in the 
pathogenesis of ARDS. Fundamental transcription abnor-
malities,  involving  NF-kappa  B  that  is  required  for  tran-
scription  of  genes  for  many  pro-inflammatory  mediators, 
are present in the lungs of ARDS patients [8]. In addition, 
other factors such as endothelin-1, angiotensin-2 and phos-
pholipase A-2 increase vascular permeability and destroy 
micro-vascular  architecture,  enhancing  inflammation  and 
lung damage. In conclusion, as several different pathways 
are involved in ARDS development, no single biomarker can 
predict outcome in ARDS patients [9].
Computed Tomography studies in the 1980s helped us 
understand the pathophysiologic alterations in the lungs of 
ARDS patients [10]. In addition, as lung compliance corre-
lates with the degree of the normally ventilated tissue, lung 
compliance decreases in ARDS because of decreased lung 
size, rather than because of lung stiffness, and this hypoth-
esis introduced the concept of ”baby lung” in ARDS [11].
Pulmonary hypertension (PH) is widely recognized as 
a characteristic feature of ARDS [12]. PH etiology includes 
parenchymal destruction and airway collapse, hypoxic pul-
monary vasoconstriction, presence of other pulmonary vaso-
constrictors and vascular compression [13].
The initial phase of fluid accumulation is followed by a 
proliferation phase characterized by resolution of pulmonary 
edema, proliferation of type II alveolar cells, fibroblasts and 
myofibroblasts, and new matrix deposition. This phase starts 
early (within 72 h) in ARDS, and lasts for more than 7 days. 
Factors influencing the progression to fibro-proliferation vs. 
resolution and reconstitution of normal pulmonary paren-
chymal architecture are poorly understood [14], but patients 
who develop pulmonary fibrosis exhibit deterioration of pul-
monary compliance, progressive hypoxia and ventilator de-
pendence, and increased mortality (> 57%) [15].
Multiple Organ Failure (MOF) is the leading cause 
of death in ARDS, but the pathophysiologic link between 
ARDS and MOF is not well defined [16]. However, based 
on existing data it is not clear whether ARDS is the mani-
festation of a disease, or it is a disease that causes the MOF 
syndrome.
Treatment
  
Improved understanding of ARDS pathophysiology and ad-
vances in technology have introduced new treatments and 
improved therapeutic strategies. The following paragraphs 
discuss recent developments in the therapeutic approach to 
ARDS.
Low tidal volume ventilation
The concept of “baby lung” was introduced in 1980s by 
Gattinoni et al and generated interest in the use of low tidal 
volume ventilation as therapeutic strategy in ARDS. Several 
animal studies showed that ventilation with large tidal vol-
umes and high inspiratory pressures resulted in development 
of hyaline membranes and inflammatory infiltrates in the 
lungs, and development of respiratory failure [17].
In  the  late  1990s  four  randomized  controlled  trials 
(RCTs) evaluated the potential benefit of low tidal volume 
ventilation in ARDS [18-21]. Although all four studies had 
limited power, one study by Amato et al [21] demonstrated 
that the low tidal volume group had higher survival, higher 
rate of weaning from mechanical ventilation and reduced 
rate of barotrauma.
Because of conflicting results from these studies, the 
National Heart Lung and Blood Institute ARDS Network 
conducted a multicenter RCT on 861 ARDS patients [22], 
comparing two group of patients ventilated with low vs. high 
tidal volumes. In-hospital mortality was significantly lower 
and the number of days without mechanical ventilation was 
significantly higher in the low tidal volume group. Although 
this study has been criticized for the high difference of tidal 
volume between groups, it demonstrated that high tidal vol-
umes should be avoided, and underlined the importance of 
maintaining low plateau pressures, with 30 cm H2O as an 
acceptable cut-off.
Low tidal volume ventilation is generally well tolerated 
and it has not been associated with clinically important ad-
verse outcomes, except for hypercapnic respiratory acidosis 
in some patients. In conclusion, hypercapnia and respiratory 
acidosis are expected consequences of low tidal volume ven-
tilation. However, there is no evidence that hypercapnia is 
harmful in ARDS patients, and it may in fact confer some 
protection against ventilator-associated lung injury.
PEEP
PEEP is an essential component of mechanical ventilation 
for patients with ARDS, as it was early observed that PEEP 
greatly improves oxygenation in ARDS patients. High PEEP 
levels may open collapsed alveoli and decrease intrapulmo-
nary shunt. Additionally, ventilation-induced alveolar injury 
is reduced by decreasing alveolar over-distention, because 
the volume of each subsequent tidal breath is shared by more 
open alveoli [23]. On the other hand, high PEEP levels may 
decrease repetitive alveolar opening and closing during the 
respiratory cycle, thereby promoting lung injury [24].
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Three RCTs have evaluated modest vs. high levels of 
PEEP in patients with ARDS. The NHLB ARDS Network 
conducted the ALVEOLI trial (Assessment of Low tidal Vol-
ume and Elevated end expiratory pressure to Obviate Lung 
Injury) [25]. This study showed improved PaO2/FiO2 ratio 
but no benefits with regards to survival or duration of me-
chanical ventilation in the high PEEP group. Several years 
later, the Canadian Critical Care Trials Group performed a 
similar study to determine whether the combination of low 
tidal volume ventilation with high PEEP could improve mor-
tality to a greater extent compared to low tidal ventilation 
alone [26]. Results of this study showed reduced need for 
other rescue therapies such as prone position or NO, but did 
not show any benefit in survival.
In conclusion, based on published data, high levels of 
PEEP do not seem to confer any benefit with regards to mor-
tality in ARDS. Because ARDS patients are a heterogeneous 
population, the apparent absence of benefit from high levels 
of PEEP could be due to the beneficial effects of high PEEP 
in some ARDS patients being offset by detrimental effects in 
other patients [27]. However, data from the RCTs mentioned 
above suggest that high PEEP levels improve lungs function 
without any adverse effect on mortality [28].
Recruitment maneuvers
A recruitment maneuver is a transient increase of trans-pul-
monary pressure intended to promote reopening of collapsed 
alveoli [29]. Techniques described for recruitment maneu-
vers include sustained high-pressure inflation and increased 
PEEP, with concurrent reduction of tidal volume [30], but 
it is not clear if any maneuver is superior to others. Several 
studies have shown improved gas exchange with recruitment 
maneuvers, but no RCT has shown benefit on ARDS mor-
tality [31] and a recent systematic review by Fan et al [32] 
showed that hypotension and decreased saturation occur in 
12% and 8% of patients respectively during or after such ma-
neuvers. Based on currently available data, although routine 
recruitment maneuvers are not recommended in ARDS, such 
maneuvers can dramatically improve oxygenation in certain 
patients, and should be considered as rescue therapy in pa-
tients with life-threatening refractory hypoxia [33].
Prone position
Prone positioning has been used in ARDS for over 30 years. 
In 1976 Piehl et al. reported improved oxygenation in ARDS 
patients when they were turned to the prone position [34]. 
Since then, several observational studies on ARDS have 
found similar results, and improvement in oxygenation can 
sometimes be dramatic [35]. Mechanisms proposed to ex-
plain the observed beneficial effects of prone positioning 
include increased chest wall elastance decreased compres-
sion of lung tissue in the dependent regions and recruitment 
of alveoli, more homogeneous ventilation due to decreased 
ventilation-perfusion inequalities and reduced ventilator in-
duced lung injury [36].
Four RCTs have investigated the effect of prone posi-
tioning on outcome. The first trial by the Prone-Supine Study 
group randomized 304 patients with a wide range of severity 
of acute lung injury [37].Patients remained prone for 7 h/
day on average, for up to 10 days, but there was no effect on 
survival. Three years later, Guerin et al conducted a similar 
multicenter study [38]: patients remained prone for about 8 
h/day, and prone positioning continued until clinical criteria 
for improvement were met, but this study also did not show 
a reduction in mortality. Two subsequent RCTs attempted to 
correct some shortcomings of the earlier study: they only in-
cluded patients with ARDS, and patients remained prone for 
most of the day (about 20 h). The first RCT by Mancebo et 
al was terminated prematurely, after only including 142 pa-
tients, because of problems with patient recruitment [39]. A 
more recent multicenter RCT by Taccone et al, included 344 
patients [40], and showed significantly increased frequency 
of adverse events (airway obstruction, hypotension, vom-
iting, accidental extubation) in patients treated with prone 
position. Neither of the last two studies showed any surviv-
al benefit using the prone position in patients with severe 
ARDS.
In conclusion, existing data do not support routine use of 
the prone position in ARDS. However, because all published 
studies have shown improved oxygenation, prone position-
ing is an attractive rescue treatment for ARDS patients with 
severe hypoxemia, even though a survival benefit has never 
been demonstrated.
High-frequency ventilation
The idea of high frequency ventilation (HFV) is to provide 
tidal volumes below that of anatomic dead space at high fre-
quency (> 60 breaths per minute). Compared to conventional 
mechanical ventilation, mean airway pressure is higher [41]. 
Two studies, by Hamilton and Chan, showed reduced risk for 
barotrauma and lung over-distention, after performing high 
frequency ventilation [42, 43]. High frequency ventilation 
can be applied by different modes, such as high-frequency 
percussive ventilation, high-frequency jet ventilation and 
high-frequency oscillatory ventilation (HFOV) [44]. In the 
absence of studies showing superiority of one method over 
another, HFOV is the HFV method used more often in adult 
critical care [43].
In HFOV very small tidal volumes (1 - 4 ml/kg) are de-
livered at high frequency (3 - 15 Hz) by an oscillatory pump 
[45]. However, the use of HFOV as rescue therapy in pa-
tients with refractory hypoxia remains controversial. There 
are two RCTs comparing HFOV with conventional mechani-
cal ventilation. The first RCT by Derdak et al found a trend 
for decreasing 30-day mortality [46] even though relatively 
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high tidal volume was used in the control group. The second 
RCT by Bollen et al was terminated prematurely because 
of slow enrollment, but found an opposite trend in mortal-
ity [47]. Two meta-analyses also had conflicting results. The 
first one included only 2 RCTs comparing HFOV vs. con-
ventional ventilation, and did not find any mortality reduc-
tion or improvement of oxygenation [48]. However, a more 
recent study by Sud et al included 8 RCTs and found reduced 
30-day mortality with HFOV compared to conventional ven-
tilation [49]. In conclusion, the role of HFOV in ARDS is 
not well defined, and deserves further study from well de-
signed RCTs.
Supportive treatment of ARDS
Fluid management
Early  data  indicate  that  increased  fluid  administration  is 
correlated with worse outcome in ARDS, whereas negative 
fluid balance was associated with better outcome [50]. The 
ARDS network conducted a RCT with 1000 patients ran-
domized to receive conservative or liberal fluid administra-
tion. The conservative strategy group showed improved lung 
function and shortened duration of mechanical ventilation, 
but there was no difference in non pulmonary organ failures 
and 60-day mortality.
Transfusions
Allogenic blood transfusion is associated with detrimental 
immuno-modulatory effects that may result in ARDS [51]. 
Consequently, conservative transfusion strategies may de-
crease the incidence of ARDS.
Sedation
Several studies have shown that newer ventilation strate-
gies using low tidal volume and high levels of PEEP do not 
require high doses of sedation [52]. Furthermore, evidence 
suggests that use of sedatives may increase duration of me-
chanical ventilation and ICU length of stay and may even be 
associated with higher mortality [53]. In addition, there is 
evidence that spontaneously breathing ARDS patients have 
improved cardiopulmonary function, presumably by recruit-
ing non ventilated lung units [54]. Therefore, based on cur-
rent evidence, avoidance or minimization of sedation and 
paralysis is preferred in ARDS.
Neuromuscular blocking agents
Administration of neuromuscular blocking agents (NMBA) 
in addition to sedation can result in improvement in severe 
hypoxemia, because paralysis improves patient-ventilator 
synchronism and reduces oxygen consumption [55]. Muscle 
relaxation may also improve chest wall compliance. NMBAs 
may also have anti-inflammatory effects that could decrease 
the inflammation associated with ARDS. However, because 
there is evidence that NMBAs increase the risk of acquired 
neuromuscular weakness, thereby making weaning from 
mechanical ventilation more difficult, and may even increase 
mortality [56].
Nutrition
Two RCTs  [57, 58] and a meta-analysis by Puntes-Arruda 
et  al  [59]  showed  that  administration  of  enteral  nutrition 
containing high concentrations of eicosapentanoic acid and 
γ-linoleic acid and ω-3 fatty acids increased oxygenation and 
decreased ICU stay and 28-day mortality in ARDS.
Pharmacologic agents 
Vasodilators
Because diffuse pulmonary vasoconstriction is part of ARDS 
pathophysiology, selective vasodilatation of well ventilated 
areas seems an attractive method to improve gas exchange in 
ARDS patients.
Inhaled nitric oxide (iNO) causes vasodilation of venti-
lated lung units and redistribution of pulmonary blood flow 
away from non-ventilated lung areas, without adverse sys-
temic hemodynamic effects. Four RCTs evaluated the effects 
of iNO and showed transient improvement in oxygenation 
[60-63],  but  no  improvement  in  mortality.  Similarly,  one 
meta-analysis found transient oxygenation improvement but 
no survival benefit with iNO [64]. Consequently, iNO may 
be useful as short-term rescue therapy in patients with severe 
hypoxemic respiratory failure.
Inhaled prostacycline is another selective pulmonary 
vasodilator. Importantly, liposomal PGE1 influences neu-
trophil function and decreases neutrophil accumulation 
and lung leak. Although inhaled prostacycline improves 
oxygenation, it has not been shown to reduce duration of 
mechanical ventilation or mortality in ARDS patients [65]. 
Despite the lack of sufficient data supporting the use of 
prostacycline as alternative to iNO, prostacycline is increas-
ingly used as pulmonary vasodilator, because of the high 
cost of iNO [66].
Vasoconstrictors
Vasoconstrictors can improve oxygenation in ARDS patients 
by decreasing intrapulmonary shunt. Phenylephrine [67] and 
almitrine [68] have been used in small studies, mainly as 
adjuncts during administration of NO. B-blockers have also 
been shown to increase arterial oxygenation in patients with 
ARDS [69]. However, the role of these agents in ARDS has 
not been adequately evaluated, and deserves further study.
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Anti inflammatory agents
The  interaction  between  nuclear  factor-kappa  B  (NF-kB) 
and glucocorticoid receptor alpha (GRa) is a key mechanism 
regulating the progression of systemic and pulmonary in-
flammation in ARDS [70]. The ability of GC-GRa to down-
regulate NF-kB activation is critical for the resolution of sys-
temic and pulmonary inflammation in ARDS [71]. Although 
several studies showed that corticosteroids confer no benefit 
and may even cause harm [72], corticosteroids are still used 
in clinical practice.
Timing of corticosteroid administration and duration of 
therapy may be important, and should be taken into consid-
eration. A RCT conducted by the ARDS Network, random-
ized 180 patients with persistent (> 7 days) ARDS, to receive 
methylprednisolone (2 mg/kg/d) or placebo for 21 days, and 
showed improved oxygenation and more ventilator-free days 
in the methylprednisolone group, but no significant improve-
ment in mortality [73]. Another RCT evaluated early cortico-
steroid administration, and showed that methylprednisolone 
administration (1mg/kg/d) [74] less than 72 after the onset of 
ARDS reduced mortality. However, these results should be 
interpreted with caution, because this study included a large 
number of patients with septic shock.
Conflicting  data  exist  concerning  the  correlation  be-
tween corticosteroids and ICU neuromyopathy. A sub-analy-
sis of study survivors did not show any association between 
randomization to corticosteroids and increased risk of neuro-
myopathy [75]. In conclusion, the relationship between cor-
ticosteroids and ICU neuromyopathy is an important issue 
that deserves further study [76].
Several other anti-inflammatory factors like Ibuprofen 
[77], ketoconazole [78], neutrophil elastase inhibitors (ONO 
5046)  [79],  NF-KB  inhibitors  [80],  recombinant  soluble 
complement receptor-1 [81], and liposomal prostaglandin E1 
[82] have been evaluated in ARDS patients without success.
Beta agonists
There are substantial evidences that b2-agonists may play a 
potential role in the treatment of patients with ARDS. B2 ag-
onists have been found to have anti-inflammatory effects by 
direct influence on neutrophil function and by reducing the 
secretion of several pro-inflammatory cytokines. Addition-
ally, b2-agonists can reduce the endothelial permeability and 
stimulate the fluid clearance from the lungs [83]. In a small 
RCT using the thermodilution method (PiCCO), intravenous 
salbutamol (15 μg/kg/h) use for seven days reduced extra-
vascular lung water compared to placebo [84]. The effects 
of inhaled b-agonists have not, to this date, been adequately 
evaluated, but will be investigated in an ongoing study con-
ducted by ARDS network (NCT00434993)
Several other pharmacological agents, including gluta-
thione lisofylline [85], N-Acetylcysteine[86], and surfactant 
[87] have been evaluated, but none of them has been shown 
to be effective for treatment of ARDS.
Extracorporeal techniques
Extracorporeal membrane oxygenation (ECMO) has been 
studied since 1970s as a method for supporting gas exchange 
in patients failing conventional ventilation [88]. A RCT con-
ducted in 1979 showed that ECMO use had no effect on long-
term survival of ARDS patients [89]. Nowadays, ECMO is 
used to support oxygenation of patients with severe ARDS, 
thereby allowing use of decreased ventilator settings (tidal 
volume, respiratory rate, FiO2), in an attempt to minimize 
ventilator induced lung injury.
In a more recent study 180 patients with severe ARDS 
were randomized to support by ECMO vs. conventional 
treatments. This study showed significantly improved sur-
vival (63% vs. 47%, P = 0.03) at 6 months in the ECMO 
group [90]. Although no definite conclusions can be drawn 
from this study [91], the results of this study suggest that 
ECMO can be used as a rescue therapy in cases of very se-
vere ARDS.
Extracorporeal CO2 removal (ECCO2R) is an alter-
native device that uses veno-venous circuit for removal of 
CO2 at much lower extracorporeal flow rates compared to 
ECMO. A RCT conducted before the year 2000 used EC-
CO2R and showed no effect on mortality [92]. In another 
study ECCO2R was combined with low frequency positive 
pressure ventilation (2 - 3 b/min), and showed improvement 
in  lung  mechanics  [93].  Overall,  extracorporeal  support 
technologies produce significant temporary improvement in 
ARDS patients with severe respiratory dysfunction, but this 
improvement does not seem to affect outcome. New, well 
conducted clinical studies are needed to better evaluate the 
role of ECMO and ECCO2R on survival in ARDS.
Mortality
  
Conflicting data exist about the evolution ARDS mortality 
over time. A meta-analysis by Phua et al did not find any 
mortality reduction in recent years [94], whereas another 
meta-analysis by Zambon et al. showed reduced mortality 
in recent years [4]. In the past, several studies evaluated pat-
terns of ARDS mortality over time within the same institu-
tion [95-99], and all studies, except for two [98, 99], found 
decreasing mortality in ARDS. The observed discrepancy 
between different studies may be due to different investiga-
tional methods, but we can conclude that ARDS mortality 
remains high (41 - 46%). Regardless of improvements in re-
cent years, ARDS mortality is higher in older patients and in 
medical patients [100]. However, the impact, if any, of newer 
treatment strategies on ARDS mortality has not been evalu-
ated, because most studies are referred to the period before 
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the year 2000.
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